Pfizer to Acquire Excaliard Pharmaceuticals & Excaliard has in-licensed from Isis
Excaliard has in-licensed from Isis and has internally developed an anti- scarring drug program, including multiple drug candidates, both clinical and pre-clinical, against multiple drug targets. The company has exclusive IP composition of matter patents filed on lead candidates including EXC 001. Through a separate research agreement, the company also has broad access to ISIS’s technical expertise in oligonucleotide discovery and informatics, pharmacology, toxicology and broad non-exclusive licenses to ISIS’s antisense IP estate.
The Company recently completed three Phase 2 trials with its lead product, EXC 001. Results from all three studies have demonstrated statistically significant reductions in scar severity compared to placebo. EXC 001 was also well tolerated with no important drug related adverse effects observed. Currently, there are no FDA-approved products to reduce scar severity, and the Company believes that EXC 001 is well positioned to be at the forefront of this multi-billion dollar market opportunity.
Upon completion of the acquisition, Pfizer plans to continue development of EXC 001 to address unmet medical needs in patient groups who suffer from excessive skin scarring.
“The acquisition of Excaliard is part of our corporate research and development strategy to actively complement our robust internal project pipeline with innovative and differentiated drugs from biotech partners,” said Mikael Dolsten, president, Worldwide Research and Development, Pfizer.